Novartis Pharmaceuticals: To be the top five pharmaceutical companies in the United States and the top three in China
Time of Update: 2022-10-12
Establish the China Center for Evidence-Based Medicine of Traditional Chinese Medicine, build a multi-dimensional evaluation technology system for proprietary Chinese medicines, carry out evidence-based evaluation of dominant diseases in traditional Chinese medicine, and provide guidance for the rational use of drugs in clinical practice.
Announcement of the State Food and Drug Administration on the cancellation of 42 drug registration certificates such as glucose injection (No. 83 [2021
Time of Update: 2022-10-01
In accordance with the relevant provisions of the Regulations on the Implementation of the Drug Administration Law of the People's Republic of China and the Measures for the Administration of Drug Registration, the State Drug Administration decided to cancel 42 drug registration certificates such as glucose injection.
Speak with Chinese data! Tianjin IBD Diagnosis and Treatment Quality Control Center speaks out
Time of Update: 2022-09-07
For medical professionals onlyHow to explore the experience of using IBD biologics in line with China's national conditions? Listen to the interview with Professor Cao Hailong, Department of Gastroent
Another batch of drugs passed the consistency evaluation, and more than 200 varieties have been evaluated in 2022
Time of Update: 2022-04-29
As of the disclosure date of this announcement, one domestic company, Yangtze River Pharmaceuticals, has passed the consistency evaluation of this variety .
Fangsheng Pharmaceutical also issued an announcement on the evening of March 8 that cefixime tablets passed the quality and efficacy consistency evaluation of generic drugs .
In 2024, the traditional Chinese medicine market may exceed 1 trillion yuan
Time of Update: 2022-04-15
At the same time, the investment of traditional Chinese medicine companies in the research and development of new drugs has also continued to increase .
"Local Drugs" Appeared in JAMA Oncology, New Economical and Efficient Choice for Radioactive Iodine Refractory Thyroid Cancer
Time of Update: 2022-01-26
On December 16, 2021, JAMA Oncology, a top journal in oncology, published online the results of the Phase III REALITY study of "apatinib or placebo in locally advanced or metastatic RAIR-DTC" .
The seventh batch of nationally collected varieties has met the conditions (list attached
Time of Update: 2021-12-06
According to the WeChat public account "Yao Chunqiu", some products of antibacterial drugs currently meet the conditions for entering the seventh batch of national procurement (only based on the competition pattern of enterprises ≥ 3, and other factors such as patents have not been considered for the time being) .
The huge cake of the domestic oncology drug market attracts the influx of pharmaceutical companies
Time of Update: 2021-12-03
In recent years, due to a large number of cancer patients stimulating industry demand, coupled with the increase in residents' disposable income and the expansion of medical reimbursement, the scale of China's oncology drug market has continued to expand .
Determination of chloramphenicol residues-combined technology (1
Time of Update: 2021-11-05
1) Gas chromatography-mass spectrometry (GC-MS)After the CAPs are derivatized by silanization and ionized in the mass spectrometry ionization source, several more abundant fragment ions will be generated, which is convenient for qualitative identification, and the sensitivity is high, which can reach the ng level .
Cinda Bio's dual-specific fusion protein was approved for clinical use
Time of Update: 2021-07-06
The latest announcement by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China shows that Cinda Biologics Class 1 new drug IBI302 has obtained the implied approval of a clinical trial and plans to develop the treatment of diabetic macular edema (DME) .
Lukang Pharmaceutical Cephalexin Tablets Passed Generic Drug Consistency Evaluation
Time of Update: 2021-05-21
In 2020, the domestic sales of cephalexin tablets will be approximately RMB 90 million, and the company's sales revenue of this product will be RMB 5.
Kanghong Pharmaceuticals' first-half profit was 310 million yuan, up 33% YoY
Time of Update: 2021-02-27
From January to June, the Company achieved operating income of RMB1.383 billion, up 1.03% YoY, while net income attributable to shareholders of listed companies was RMB310 million, up 33.13% YoY, and basic earnings per share was RMB0.46.
Everything has a degree of paint enterprise micro-marketing grasp a good balance
Time of Update: 2021-02-21
So, in the era of big data, coatings enterprises how to do a good job of micro-marketing?
According to the head of a paint enterprise, in the micro-marketing platform people can spread information more quickly, more convenient to save the middle circulation of the purchase costs.
Geneneck announces the latest results of SMA therapy in clinical trials
Time of Update: 2021-02-09
study patients with type 1 SMA were treated with different doses of risdiplam in a clinical trial called FIREFISH.
in sunFISH clinical trials, patients with type 2 and type 3 SMA between the ages of 2 and 25 were treated with risdiplam.
Yangzijiang Pharmaceuticals' "Entikave oral solution" was approved for the first time
Time of Update: 2021-01-19
from: Insight database () for Entekave oral solution, the original research hundred-time Meishi Guibao pharmaceutical is still in clinical applications, there are few domestic enterprises to apply.